CytRx Submits Response To FDA Related To Clinical Program With Arimoclomol In ALS
Apr 2nd 2008Drug InformationMuscular Dystrophy
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced that it has filed a response with the U.S. Food and Drug Administration (FDA) addressing issues cited by the FDA in its decision to place a clinical hold on the Company’s Phase IIb clinical trial with arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
